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Abstract
Background: Among the unique features of the Rare Diseases Clinical Research Network (RDCRN) Program is the
requirement for each Consortium to include patient advocacy groups (PAGs) as research partners. This development
has transformed the work of the RDCRN and is a model for collaborative research. This article outlines the roles
patients and PAGs play in the RDCRN and reports on the PAGs’ impact on the Network’s success.
Methods: Principal Investigators from the 17 RDCRN Consortia and 28 representatives from 76 PAGs affiliated with
these Consortia were contacted by email to provide feedback via an online RDCRN survey. Impact was measured in
the key areas of 1) Research logistics; 2) Outreach and communication; and 3) Funding and in-kind support. Rating
choices were: 1-very negative, 2-somewhat negative, 3-no impact, 4-somewhat positive, and 5-very positive.
Results: Twenty-seven of the PAGs (96 %) disseminate information about the RDCRN within the patient community. The
Consortium Principal Investigators also reported high levels of PAG involvement. Sixteen (94 %) Consortium Principal
Investigators and 25 PAGs (89 %) reported PAGs participation in protocol review, study design, Consortium conference
calls, attending Consortium meetings, or helping with patient recruitment.
Conclusions: PAGs are actively involved in shaping Consortia’s research agendas, help ensure the feasibility and success
of research protocols by assisting with study design and patient recruitment, and support training programs. This
extensive PAG-Investigator partnership in the RDCRN has had a strongly positive impact on the success of the Network.
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Background
A “rare disease” is defined by the Amendment to the
Orphan Drug Act of 1983 as a condition affecting fewer
than 200,000 Americans or a disease with a greater
prevalence but for which no reasonable expectation ex-
ists that the costs of developing or distributing a drug
can be recovered from the sale of the drug in the United
States [1]. Approximately 25 million people in the
United States are affected by one or more of an esti-
mated 7000 rare diseases or conditions. These diseases
often lead to significant morbidity and mortality.
Research into rare diseases encounters unique chal-
lenges to the scientific community, the biopharmaceut-
ical and medical device and diagnostics industries,
academic and public sector researchers, government
funding agencies, private foundations, regulatory agen-
cies, and patient advocacy groups. These challenges in-
clude difficulties in establishing diagnoses, difficulty in
recruiting subjects into clinical studies due to small pa-
tient populations distributed over wide geographic areas,
few expert centers for diagnosis, management, and re-
search, and a scarcity of investigators focused on these
rare diseases. These issues continue to be addressed with
steady advances being made in the approach to studying
rare diseases and, in parallel, substantial interest by the
biopharmaceutical industry in developing products for
the treatment of rare diseases.
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To respond to the challenges of research on rare dis-
eases the NIH Office of Rare Diseases Research (ORDR),
now located in the National Center for Advancing Trans-
lational Sciences (NCATS), established the Rare Diseases
Clinical Research Network (RDCRN) in 2003, in collab-
oration with six other Institutes and Centers (ICs) and
funded 10 Rare Diseases Clinical Research Consortia
(RDCRC) and a single Data Management and Coordinat-
ing Center (DMCC) for the whole Network [2]. The
RDCRN was expanded in 2014, in collaboration with ten
NIH ICs and currently consists of 22 research consortia
and a central DMCC. Each Consortium is required to
focus on a group of at least three related disorders, in-
clude multiple investigators at multiple sites, and collab-
orate with patient advocacy groups (PAGs). The RDCRN
is unique in its approach to addressing rare diseases as a
group, including promoting collaboration with PAGs,
and is the first program that promised to create a collab-
orative and coordinated network of investigators and pa-
tient groups to support research into rare diseases.
The RDCRN has proven to be an extremely effective re-
search model to maximize research investigator participa-
tion, initiating clinical trials, facilitating patient recruitment
with established research partnerships with PAGs at mul-
tiple research sites around the world, and enabling pharma-
ceutical industry and government sponsored clinical
research studies to proceed with a supportive infrastructure
to complete the studies in a timely fashion [3].
Among the unique features of the RDCRN is the
requirement for each Consortium to include PAGs as
research partners. This mandate has led to the develop-
ment of a vibrant culture within the Network in which the
roles of patients has grown steadily to the current state in
which patients are highly engaged in every aspect of the
work of the Consortia. This article outlines the roles
patients and PAGs play in the RDCRN and reports on
data collected to evaluate these roles and their impact on
the Network’s success.
Background, goals, and organization of the RDCRN
The purpose of the RDCRN is to facilitate multi-site clinical
research in rare diseases through support for 1) collaborative
clinical research in rare diseases, including longitudinal stud-
ies of individuals with rare diseases, clinical studies and/or
phase I, II, and II/III trials; 2) training of clinical investigators
in rare diseases research; 3) pilot and demonstration pro-
jects; 4) a test bed for distributed clinical data management
that incorporates novel approaches and technologies for
data management, data mining, and data sharing across rare
diseases, data types, and platforms; 5) collaboration with
PAGs as research partners; and 6) access to information re-
lated to rare diseases for basic and clinical researchers, aca-
demic and practicing physicians, patients, and the lay public.
The RDCRN, with the input from PAGs associated with
Consortia, has been successful in providing website resource
for education and research in rare diseases for health care
providers, patients and their families, the biopharmaceutical
and medical device industry, and research investigators [3].
Included in the RDCRN is an active Patient Contact Registry
to facilitate the recruitment of patients and communications
between investigators and patients and their families [4–6].
PAGs have contributed more than 40 % to the total num-
bers enrolled.
More than 70 PAGs are active participants in the
RDCRN. Through the direct engagement of patients,
their families and friends, PAGs led to acceptance of
these individuals and organizations as research partners
and the establishment of the Coalition of Patient Advo-
cacy Groups (CPAG) for the RDCRN. CPAG represents
the perspective and interests of all PAGs associated with
the RDCRN and includes representatives from every
PAG in the RDCRN, has its own governing structure
and leadership, and is a major component of the
RDCRN with voting privileges on the RDCRN Steering
Committee. The RDCRN-CPAG meets annually, at the
same time as the RDCRN Steering Committee, and has
standing conference calls throughout the year.
Value of patient advocacy groups as research partners
PAGs within the RDCRN are involved as research part-
ners, including helping to recruit for clinical studies, en-
couraging participation in natural history studies,
identifying cohorts of patients with a range of phenotypic
expression, and educating patients, public, media and
health care providers. Several PAGs provide financial sup-
port for research and training programs of RDCRC and
patient registries. In addition, PAGs identify research ef-
forts and translate research results to communities,
organize and fund research based scientific conferences
and meetings for patients/families/caregivers. A few PAGs
also provide financial support for patients to travel to
clinics to facilitate access to investigators and studies.
Each Consortium in the RDCRN includes relevant PAGs
in the Consortium membership and activities and the
direct involvement of PAGs in RDCRN operations,
activities, and strategy is a major feature of this network.
Methods
Principal Investigators (PIs) from the 17 RDCRN
Consortia established at time of this study and rep-
resentatives from PAGs affiliated with these Consor-
tia were contacted by email and asked to provide
feedback via an online RDCRN survey. Two comple-
mentary survey tools were developed and imple-
mented in parallel. The first survey focused on
investigators’ perceptions of the impact of Consor-
tium/PAG collaboration; a second survey, with iden-
tical or substantially similar questions, focused on
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PAGs’ perceptions of their impact on the RDCRN.
The surveys contained descriptors of the most com-
monly reported types of interactions.
Both versions of the survey consisted of seven ques-
tions. Four multi-part rating scale questions were de-
signed to elicit the perceptions of impact of the RDCRN
collaborative research model on achieving research goals
from the perspective of the Consortium PI compared
with the perceptions of the PAGs. Impact was measured
in the key areas of 1) Research logistics, including study
design, patient recruitment and administrative support;
2) Outreach and communication, including website de-
sign, patient educational meetings and development of
educational materials; 3) Funding support for RDCRC
activities; and 4) Other non-monetary forms of support.
Rating choices were scored as follows: 1-very negative,
2-somewhat negative, 3-no impact, 4-somewhat positive,
and 5-very positive. There was also an option for “not
applicable.” Responses in each category were tabulated
for an average score. Average scores for each category
were compared between the Consortium PI responses
and the PAG responses.
Additionally, two questions asked each respondent to
identify the top three benefits and top three challenges
of working collaboratively within the RDCRN model
from a prepopulated list of 17 topics selected through
consensus by representatives of the RDCRN Strategic
Planning Committee, the sub-committee of the RDCRN
Steering Committee that oversaw the survey project.
The final question utilized a free-text answer and pro-
vided an opportunity for respondents to include add-
itional commentary regarding experiences with the
RDCRN collaborative research model.
Data analysis
Responses were matched by Consortium and then anon-
ymized so as to mask respondents and their assessments.
Since there were multiple PAG respondents for several
Consortia, the median response was used to pair with the
corresponding Consortium response. Analyses were de-
scriptive and both means and medians calculated. As the
responses were on a Likert-type scale ranging from 1 to 5,
medians are generally considered the best measure of cen-
tral tendency, but means are also presented. On an inter-
val scale, medians are also less affected by outliers and the
difference can be interpreted as to the extent there are
wide variations in response. As these are purely descrip-
tive data with a high degree of concordance, no attempt
was made to test whether or not the row and column
marginal frequencies are equal.
Results
All 17 Consortia PIs and 28 of 76 PAGs associated with
the RDCRN completed the survey, with at least one
PAG representing each Consortium (range 1–3). Except
for one, the responding PAGs were established before
2010, with 13 established before 1990. There was a large
range in the number of patient/families served by these
PAGs and the reported numbers were equally split between
less < 1000, 3000–5000, and ≥10,000. 50 % of responding
PAGs reported a financial capacity of more than $1 million,
and all but 6 reported having their own research funding
program. The Consortia PIs reported that 82-100 % of their
affiliated PAGs (not just of those who responded to the
survey) collaborated on the specific items listed while
48-96 % of the responding PAGs reported collaboration
along these same dimensions (Table 1).
Interactions
The most commonly reported interactions between
Consortia and PAGs were those that involved com-
munication and outreach to the patient community.
Nearly all PAGs (27/28, 96 %) disseminate informa-
tion about Consortium activities within the patient
community via their PAG websites, newsletters, and
other forms of communication. All PIs and 86 % of
PAGs include updates for their associated Consortium
during their PAG meetings. Most PIs (88 %) and PAGs
(82 %) also provide patients with educational materials
related to Consortium activities. The areas in which the
PAGs reported less collaboration included providing
partial or full funding of Consortium trainees (46 %),
administrative support to the Consortium (50 %), direct
funding to the Consortium (57 %), logistical support to
the Consortium for meetings (64 %), and review of study
forms and other study related documents (68 %).
The Consortium PIs also reported high levels of PAG in-
volvement in Consortium research activities. Sixteen of the
17 (94 %) Consortium PIs and 25 of the 28 (89 %) respond-
ing PAGs reported PAG participation in protocol review,
study design, Consortium conference calls, attending
Consortium meetings, or helping with patient recruitment.
These data suggest active PAG involvement in shaping the
Consortia’s research agenda and contributing to ensuring
the feasibility and success of research protocols by assisting
with patient recruitment. Additionally, 82 % of PIs and
64 % of PAGs indicated that the PAGs provided logistical
or administrative support to their Consortium.
All but one PAG indicated that they played an active
role in communicating Consortium activities to their
membership through social media, newsletters and other
means. These are the primary means by which PAGs
mobilized their membership to enhance recruitment
efforts. A substantial percentage (82-86 %) of PAGs
provided time at their meetings for presentation and
discussion of Consortium activities and dissemination of
educational materials developed by their affiliated
Consortium. A similar percentage (79 %) of PAGs also
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contributed to the Consortium website development. In
the RDCRN, each Consortium maintains a public-facing
web presence to communicate to the larger community
of investigators, care givers, and patients about the Con-
sortium’s specific collection of rare diseases.
Thirteen (76 %) PIs indicated that their Consortia re-
ceive direct funding from one or more of their associated
PAG(s). In all but one instance, this support included par-
tial or full funding of RDCRN trainees (including travel to
meetings). Nine of the 13 (69 %) Consortium PIs reported
that they have received a total of at least $100,000 from
their associated PAGs. One PAG has provided $2.25
million in direct financial support for a Consortium’s
activities. Two (12 %) Consortium PIs reported the level
of support to be between $10,000 and $49,000, and 2 did
not indicate a level of funding. Eighteen of the 28 (64 %)
PAGs responding indicated they provide funding support
for Consortium meetings/activities. In addition to direct
funding, 17 of the 28 (61 %) PAGs provide in-kind support
for Consortium activities, such as mailings or office staff.
One of the four Consortia that did not receive direct
funding reported that they received in-kind support.
Table 1 RDCRN consortium-patient advocacy group partnership survey response
Survey question: what impact has your
(associated) PAG(s) had with your RDCRN
consortium activities in each of the
following areas?
Consortium PIs (N = 17) PAGs (N = 28)
Engage in activity (%) Mean Median Engage in activity (%) Mean Median
Research
Review protocols and provide substantive
input on study design
14 (82) 4.2 5 21 (75) 4.5 5
Review study forms and other study
related documents
16 (94) 4.3 4 19 (68) 4.6 5
Participate in Consortium conference calls 16 (94) 4.6 5 25 (89) 4.7 5
Attend Consortium investigator meetings 16 (94) 4.8 5 21 (75) 4.8 5
Help with patient recruitment for
RDCRN studies
16 (94) 4.7 5 24 (86) 4.5 5
Provide logistical support for Consortium
meetings, calls, etc.
14 (82) 4.2 4.5 18 (64) 4.3 5
Provide administrative support to Consortium 14 (82) 3.8 3.5 14 (50) 4.3 4.5
Communication/Outreach
Contribute to Consortium website
design and content
14 (82) 4.5 5 22 (79) 3.9 4
Include Consortium activities, updates
or relevant sessions at PAG meetings
17 (100) 4.7 5 24 (86) 4.6 5
Communicate Consortium activities
within the patient community through
website, newsletters, etc.
17 (100) 4.8 5 27 (96) 4.7 5
Provide educational materials related
to Consortium activities for
patient community
15 (88) 4.9 5 23 (82) 4.6 5
Funding
Provide direct funding to the Consortium 13 (76) 4.5 5 16 (57) 4.3 5
Provide funding support for Consortium
meetings/activities
14 (82) 4.4 5 18 (64) 4.1 4
Provide partial or full funding for
Consortium trainees




(e.g., mailings, office staff, other)
14 (82) 4.4 4 17 (61) 4.4 5
RDCRN Rare Diseases Clinical Research Network, PIs principal investigators, PAG patient advocacy group
Scale: 1 = very negative, 2 = somewhat negative, 3 = no impact, 4 = somewhat positive, 5 = very positive. N total number of Consortium PIs or PAGs that
participated in the survey
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Impact
When PAG responses were compared to those from the
PI of their affiliated consortium, there was a high degree
of concordance (Table 2). Averaging over all questions,
there were no Consortia responses less than “somewhat
positive” (a score of 4.0) and 14 of 17 ranked the inter-
action as “very positive” (a score of 5.0). For the Consor-
tium PIs, the ratings ranged from a mean of 3.8
(“provide administrative support to a Consortium,” the
only item in which the mean was less than 4.0) to 4.9
(“provide educational materials related to Consortium
activities for patient community”). Similarly, only 1 of
the 17 Consortia received an average score across all re-
sponses of 3 (“no impact”), the remainder were either
“very positive” or “somewhat positive” (9 and 7, respect-
ively). The item that received the lowest PAG rating,
with a mean score of 3.9, was “contribute to Consortium
website design and content.” That was the only item in
which the mean was less than 4.0) and the item with the
highest mean rating for impact was 4.8 (“attend Consor-
tium investigator meetings”).
When asked to rank the top three benefits accrued to
the Consortium through their interactions with PAGs
(Table 3), the most frequently cited benefits were help
with patient recruitment for RDCRN studies (11 of 15
respondents, 73 %), communication of Consortium ac-
tivities within the patient community (6 of 15 respon-
dents, 40 %), and providing direct funding to the
Consortium (4 of 15 respondents, 27 %). The top three
benefits for the PAGs were participation in Consortium
conference calls (15 of 28 respondents, 54 %), inclusion
in Consortium activities (14 of 28, 50 % or respondents),
and help with patient recruitment for RDCRN studies
(13 of 28 respondents, 46 %). The other benefits re-
ported were distributed widely across respondents with
3 or fewer Consortia and 6 or fewer PAG respondents
emphasizing their benefit.
All respondents were also asked to provide feedback
on their top 3 challenges in working collaboratively
(Table 4). These choices were drawn from the same list
as the benefits, and reflecting those results, the top chal-
lenge for Consortia PIs was funding (4 of 15 responses)
and, for PAGs, desire for input into protocol develop-
ment (6 of 26 responses).
Table 5 contains the individually-reported comments
from the Consortium PIs and the PAGs to give a
broader flavor of the nature of the interactions.
Discussion
This study describes the successful approaches and com-
mon challenges in directly engaging patients and PAGs
with investigators in the creation, growth, and product-
ivity of multicenter research groups involved in clinical
research in rare diseases. The ten-year experience of the
RDCRN has been one of great success and scientific
productivity. The RDCRN investigators, affiliated PAGs
and patient leaders, ORDR-NCATS and collaborating
Institutes’ program staff at NIH, and other key stake-
holders all agree that the substantial partnership and in-
volvement of patients, from the start, has been a major
factor in the success of the Network and helped the
Consortia conduct important research in a large of num-
ber of rare diseases. The investigator-patient partnership
has contributed to the development of the Network on
multiple levels and patients and PAGs have been in-
volved in research in the RDCRN in a wide variety of
ways.
The results of this study describe numerous ways in
which PAGs and RDCRN investigators work together to-
wards common goals for many different types of studies.
This degree of involvement by PAGs is not typical of
most NIH-funded research. There was strong agreement
among both PAG representatives and RDCRN investiga-
tors that these collaborations usually had a positive
impact.
One of the major challenges for any clinical study
is recruitment of appropriate participants in a timely
manner. Through their existing web sites and often
regular patient support group meetings, the PAGs
positively influence recruitment for clinical studies by
educating potential participants about the value of
clinical studies in general, advertising specific studies
directly, answering questions about specific studies,
and providing feedback on outcomes in some cases.
In view of these factors, it is not surprising that com-
munication and outreach were ranked among the
most impactful aspects of interaction by both PAGs
and RDCRN investigators.
In many cases, PAGs have a direct influence on the
types of scientific projects that are initiated by providing
direct funding for specific projects or specific investiga-
tors. The investigators, in turn, sometimes provide ad-
vice on independent scientific projects that the PAGs
Table 2 Concordance between consortium principal
investigators and corresponding patient advocacy group
responses













very negative 0 0 0 0 0
somewhat
negative
0 0 0 0 0
no impact 0 0 0 0 0
somewhat
positive
0 0 1 3 2
very positive 0 0 0 4 7
PIs principal investigator, PAG patient advocacy group
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may be considering through service on their scientific
advisory boards. Additionally, many PAGs recognize the
importance of attracting a new generation of investiga-
tors and they often provide financial support for trainee-
led research projects or trainee attendance at Consor-
tium or other relevant meetings. All of these activities
were also rated as having important impact by both
PAGs and RDCRN investigators.
The RDCRN, with the input from PAGs associated
with Consortia, has been successful in providing
website resource for education and research in rare
diseases for health care providers, patients and their
families, the biopharmaceutical and medical device
industry, and the research investigators. Many PAGs
have at least some educational material on their web
sites, brochures, or newsletters, and the RDCRN
Consortia have similar educational material on their
web sites. A close collaboration between PAGs and
investigators can be useful in confirming the accur-
acy of the information provided and ensuring the
language used is written at a level and in a style ac-
cessible to most patients and their families.
An important and unique component of the RDCRN
is an active Patient Contact Registry to facilitate the re-
cruitment of patients and communications between in-
vestigators and patients and their families. PAGs are the
single largest source of referrals to the Patient Contact
Registry [7, 8].
Table 3 Top benefits of consortium-patient advocacy group interactions
Principal investigators Patient advocacy groups
Benefit No. of PIs selecting % of 15 investigators
answering question




3 20 % 14 50 %
Communicate Consortium activities
within the patient community
6 40 % 6 21 %
Contribute to Consortium website
design and content
2 13 % 1 4 %
Help with patient recruitment for
RDCRN studies
11 73 % 13 46 %
Include Consortium activities, updates
or relevant sessions at PAG meetings
1 7 %
Include Consortium activities, updates
or relevant sessions at PAG meetings
6 21 %
Other communication activities 3 11 %
Other research activities 1 7 % 4 14 %
Participate in Consortium
conference calls




Provide direct funding to the
consortium
4 27 % 3 11 %
Provide educational materials related
to Consortium activities for
patient community
2 13 %
Provide funding support for Consortium
meetings/activities
2 13 %
Provide logistical support for Consortium
meetings, calls, etc.
3 20 % 1 4 %
Provide partial or full funding for
Consortium trainees
3 20 % 1 4 %
Received funding or other support
from Consortium
2 7 %
Review protocols and provide
substantive input on study design
2 13 % 2 7 %
Review study forms and other
related documents
1 7 % 3 11 %
PIs principal investigators, PAG patient advocacy group
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The experience of the RDCRN and the data presented
in this study demonstrate that direct patient engagement
in the development of research networks and design and
conduct of research projects is feasible, and highly
regarded in the conduct of clinical research in rare dis-
eases. PAGs are ready, willing, and able to participate in
all aspects of research, including study design, recruit-
ment, research prioritization, funding strategies, and dis-
semination of research results. The support and
direction provided by the Office of Rare Diseases Re-
search within the NCATS for the RDCRN was also es-
sential for the development of the investigator-patient
partnerships. The experience of the RDCRN can be ap-
plied to other groups studying rare diseases and to
groups studying more common disorders. RDCRN prin-
cipal investigators and leaders of the associated PAGs all
agree that the quality, quantity, efficiency, and pace of
clinical research in rare diseases is greatly enhanced by
the types of investigator-patient partnerships that have
developed within the RDCRN.
These results are consistent with other studies of pa-
tient engagement [9–12]. Those studies also identified
the key role that PAGs play in patient recruitment iden-
tified by academic researchers and PAGs alike, reflecting
the highly positive results of PAG interactions with in-
vestigators. This study adds to that literature by
highlighting the area of communication and dissemin-
ation of study results. However, these results differ from
the CTTI report [9] that also found patient group re-
spondents valued their contributions to research proto-
col development, funding, and interpretation of study
results more highly than those contributions were valued
by academic respondents. This RDCRN study found that
these components of interaction were generally equally
Table 4 Top challenges of consortium-patient advocacy group interactions
Principal investigators Patient advocacy groups
Benefit No. of PIs selecting % of 15 investigators
answering question




1 7 % 3 12 %
Communicate Consortium




website design and content
1 7 % 1 4 %
Help with patient recruitment
for RDCRN studies
1 7 % 4 15 %
Include Consortium activities,
updates, or relevant sessions
at PAG meetings
1 4 %
Other communication activities 4 15 %
Other research activities 1 7 %
Participate in Consortium
conference calls




Provide direct funding to the
Consortium
4 27 % 1 4 %
Provide funding or other
support to PAGs
1 7 %
Provide funding support for
Consortium meetings/activities
1 7 %
Provide partial or full funding
for Consortium trainees
2 13 % 1 4 %
Received funding or other
support from Consortium
2 8 %
Review protocols and provide
substantive input on study design
2 13 % 6 23 %
Review study forms and other
related documents
1 7 % 4 15 %
PIs principal investigators, PAG patient advocacy group
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rated in terms of impact and importance by PAGs and
Consortium PIs. The reluctance to share information
perceived by investigators and patient group members in
the CTTI study was not found in this RDCRN study in
which PAGs were seen as playing an important role in
dissemination of information and study results. This may
be due to the way that PAGs have been integrated from
the start into RDCRN Consortium activities and are con-
sulted in study design and development. Through monthly
RDCRN-CPAG conference calls and annual in-person
meetings, PAGs also have the opportunity to share their
experiences, learn from each other, and gather informa-
tion about resources and scientific programs at ORDR,
NCATS, and other Institutes of NIH.
The RDCRN has utilized its strong platform for col-
laboration between PAGs and investigators to produce a
highly productive synergy that can serve as a model of
patient engagement in conducting clinical research, es-
pecially in rare diseases. Additionally, this development
of substantial patient engagement has transformed the
Table 5 Individual free text comments from RDCRN consortium
principal investigators and patient advocacy groups
Patient advocacy group
Development and growth of the Consortium-sponsored symposia has
had a tremendously positive effect on the rare disease community.
Assisting in recruitment through specific protocols and through
conferences has been very rewarding. Additionally data derived on
and subsequently published has made an immediate impact to the
patient and medical community. This has been made possible
through RDCRN. Working with other investigators and PAGs has also
provided opportunities to learn from each other through professional
interaction.
A big challenge was understanding the limits of the contact registry.
[The PAG is] responsible for getting >91 % of patients who are
registered. Yet, we could not access those patients nor did the
patients receive significant benefit
I am very happy to be the PAG representative. It would be wonderful
if someone took notes on conference calls for those who cannot
make them.
During the first couple of years the PAGs had a monthly conference
call with the project manager to discuss what was going on. Would
be good to reinstate these calls - maybe on a quarterly basis to keep
PAGs up-to-date.
Expanding our relationship with our PIs through Consortium activities
has been one of the most fulfilling parts of our involvement in the
RDCRN. The Consortium has been a wonderful platform to expand
our outreach & growth to the affected community. It has been
wonderful to work with investigators and PAGs from other Consortia
and to learn from their experiences. We are forever grateful to the
RDCRN and hope to continue this partnership for years to come.
In the first few years of our Consortium it was an uphill rocky climb
to get researchers to accept and trust our PAG input related to how
best to engage and recruit participants and to enroll participating
research sites. With continued communication and low turnout
becoming evident the tide has now turned for the better and we are
seeing our input now valued and increased patient participation.
Our PAG became very involved with the RDCRN in about 2005, and
involvement has been steady and positive since that time, but ebbs
and flows with renewals and travel site scheduling. Involvement in
the study design is highest and most collaborative right now in 2013
with our PAG interest in 2014 renewal. RDCRN has been very
responsive to our PAG on any data questions and publishing on
issues important to our community that can be revealed by the
database.
Our PAG is pleased with the positive results of our collaboration.
Our Consortium is quite different from most others in that there is
not a clinical trial associated with it (yet). The focus is on basic and
translational research and the PAG-researcher relationship has been
very constructive in that space.
The [Consortium] PAGs are still mostly arm's length from operations.
Leadership wants to be open but on a practical basis operates in a
fairly closed circle.
The cooperation and communication between the PAGs and the PIs
has been wonderful. It has strengthened the community as we feel
we are all working together for a common goal. The researchers
respect and embrace the role the PAGs play to help support the
Consortium and together we are moving research forward impacting
the lives of patients. It has also allowed for smaller PAGs to make an
impact on research by supporting programs like Travel Scholarships
helping with recruitment and promoting the work of the
[Consortium].
Time is a challenge - we would like to participate more. We include
Consortium activities in our newsletter.
Table 5 Individual free text comments from RDCRN consortium
principal investigators and patient advocacy groups (Continued)
Wonderful collaborative relationship and feel like we have been
accepted as equal partners.
Principal investigator
Our relationship with our associated PAGs is excellent and our PAGs
are an essential component to the success of our Consortium.
Overall the Consortium has benefited significantly from the support
of PAG groups affiliated with it.
Our PAGs have been very supportive in communicating our study
and research activities to the patient community, and providing in-
kind support by sending out letters describing our studies or printing
educational materials, etc. They have provided some trainee support
in the form of travel scholarships to attend respective scientific meet-
ings hosted by the PAG.
Support from our PAGS has allowed us to add multiple sites to our
RDCRC. Without their support we would not be able to accomplish
much of what we have done over the past 4 years
The PAG has been involved in all aspects of the Consortium activities
and all interactions have been only positive
The PAGs are an enormous asset to the Consortia and they are
becoming a greater asset as time goes forward.
The PAGs try very hard to help and they do help meaningfully in
some ways. They are very busy have day jobs and little resources.
Also they are lay people do not express interest in reviewing study
documents.
The regular intellectually invested and committed involvement of our
PAG is the key benefit… it really helps to have constant feedback
and input. It would be a bonus if they could be able to provide some
funding but that is a secondary issue for us.
The partnership of our PAGs and the Consortium has been very
effective toward achieving our common mission of advancing
understanding of these diseases developing more effective
treatments and assuring that all patients have access to current
correct information. Much more is achieved by this partnership than
would be possible by either of us working alone.
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work of the RDCRN and is a model for collaborative
research.
Conclusions
Results suggest active involvement by PAGs contribute to
shaping Consortias’ research agendas and contribute to
ensuring the feasibility and success of research protocols
by assisting with patient recruitment. This extensive in-
volvement is the basis for the positive impact of PAG-
Investigator partnership in the RDCRN.
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